According to the search, the country has actually considered it for a long time. It is reported that the enterprise will control the cost at around 1,, which is very cost-effective. If it can enter medical insurance in the next step, according to the reimbursement quota of 6%, the personal burden will be smaller, so that more families can hope to cure cancer.
At the end of p>221, Chongqing Gaojin Biotechnology Co., Ltd. announced the successful development of BPA boron drug, and it is expected that it can be used in clinic in 223. It is claimed that this drug can remove cancer cells within 3 minutes, and is currently mainly used to treat a variety of malignant tumors, including glioma, brain cancer and melanoma.